Screener
Jazz Pharmaceuticals JAZZ Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Ordinary shares | — | — |
| Non-voting euro deferred shares | 0.1 | 0.1 |
| Capital redemption reserve | 0.5 | 0.5 |
| Additional paid-in capital | 4,243.5 | 4,240.5 |
| Accumulated other comprehensive loss | (651.0) | (568.6) |
| Retained earnings | 939.2 | 646.1 |
| Total shareholders’ equity | 4,532.3 | 4,318.6 |
| Total liabilities and shareholders’ equity | $11,859.6 | $11,659.3 |
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's total liabilities & equity?
- Jazz Pharmaceuticals (JAZZ) reported total liabilities & equity of $11.86B in Q1 2026.
- How has Jazz Pharmaceuticals's total liabilities & equity changed year-over-year?
- Jazz Pharmaceuticals's total liabilities & equity increased by 2.8% year-over-year, from $11.53B to $11.86B.
- What is the long-term trend for Jazz Pharmaceuticals's total liabilities & equity?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's total liabilities & equity has grown at a 12.3% compound annual growth rate (CAGR), from $6.54B to $11.66B.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about Jazz Pharmaceuticals's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude